News

Dr Schoenberg will assist the company in its current effort to complete critical clinical trials with the Sonablate 500 technology in the treatment of patients with prostate cancer.

The Cayman product family is comprised of multiple implant systems, including a buttress plate to address graft expulsion, a lower lumbar sacral plate, and additional plating designs to

The new agreement extends the most recent agreement for an additional three years with two consecutive one year renewal options. The Bioject drug vial adapter is a needle-free

Sodium-dependent glucose co-transporter type 2 (SGLT2) is the major transporter responsible for glucose re-absorption in the kidney. Decreasing SGLT2 levels promote glucose excretion in the urine and reduce

Earlier, the company submitted its response to the FDA complete response letter for paliperidone palmitate, received in August 2008. Paliperidone palmitate is an investigational once-monthly atypical antipsychotic injection

The investment, which originated from Paul Manning, a director of the National Neurovision Research Institute (NNRI), is supporting the continuing development of StarGen. StarGen is Oxford BioMedica’s novel

The award funds continued development of PL 4500, a molecular complex of indomethacin and phosphatidylcholine that is being developed as a gastrointestinal (GI) safer anti-inflammatory and analgesic in

Under a collaboration agreement between the University of California, San Diego (UCSD) and Raptor, UCSD is conducting the Phase IIa clinical trial at UCSD’s General Clinical Research Center.

Further, AspenBio Pharma said it promoted Mark Colgin to a new position of chief scientific officer. “We are very grateful for Rich’s invaluable contribution over the last few